Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG238

—

7c3ec62c-f374-525b-97fa-8ac6ea379fd4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TGF_BETA_SIGNALING+0.393
  • NOTCH_SIGNALING+0.262
  • HEDGEHOG_SIGNALING+0.241
  • UV_RESPONSE_DN+0.225
  • WNT_BETA_CATENIN_SIGNALING+0.221
  • BILE_ACID_METABOLISM+0.211
  • PROTEIN_SECRETION+0.189
  • ESTROGEN_RESPONSE_EARLY+0.177
  • PEROXISOME+0.149
  • P53_PATHWAY+0.148

Top 10 suppressed

  • E2F_TARGETS-0.349
  • ALLOGRAFT_REJECTION-0.281
  • G2M_CHECKPOINT-0.244
  • INTERFERON_GAMMA_RESPONSE-0.213
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.199
  • INTERFERON_ALPHA_RESPONSE-0.189
  • HYPOXIA-0.170
  • MYC_TARGETS_V1-0.142
  • INFLAMMATORY_RESPONSE-0.121
  • MTORC1_SIGNALING-0.110

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG905
mng-umap@100
——0.780
2DRR168545
bladder-landscape@3
——0.780
3ULC0569T_S27
lung-landscapes@6
—cohortA10.780
4TCGA-A2-A3KD-01A-12R-A213-07
breast-umap@18
—A0.769
5TCGA-BH-A0DO-01B-11R-A12D-07
breast-umap@18
—A0.760
6TCGA-44-6146-01A-11R-1755-07
lung-landscapes@6
—cohortA10.759
7TCGA-75-6206-01A-11R-1755-07
lung-landscapes@6
—cohortA20.757
8TCGA-E2-A1L6-01A-11R-A13Q-07
breast-umap@18
—A0.748
9TCGA-AC-A2FG-01A-11R-A17B-07
breast-umap@18
—A0.747
10TCGA-B6-A1KI-01A-11R-A14M-07
breast-umap@18
—B0.746

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TGF_BETA_SIGNALING0.393Inavolisib— uncovered
NOTCH_SIGNALING0.262Inavolisib— uncovered
HEDGEHOG_SIGNALING0.241Inavolisib— uncovered
UV_RESPONSE_DN0.225Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.221Inavolisib— uncovered
BILE_ACID_METABOLISM0.211Inavolisib— uncovered
PROTEIN_SECRETION0.189Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.177Inavolisib— uncovered
PEROXISOME0.149Idelalisib— uncovered
P53_PATHWAY0.148Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.145Inavolisib— uncovered
ANDROGEN_RESPONSE0.129Inavolisib— uncovered
HEME_METABOLISM0.118Temsirolimus— uncovered
ESTROGEN_RESPONSE_LATE0.116Idelalisib— uncovered
APICAL_JUNCTION0.078Inavolisib— uncovered
FATTY_ACID_METABOLISM0.058Inavolisib— uncovered
APOPTOSIS0.051Idelalisib— uncovered
APICAL_SURFACE0.042Temsirolimus— uncovered
MYOGENESIS0.039Inavolisib— uncovered
ANGIOGENESIS0.035Remibrutinib— uncovered